Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Ewing sarcoma is a rare type of cancer that usually grows in the bones or the soft tissue around them. While standard treatments work well for many, it is much harder to treat if the cancer returns or stops responding to therapy. This clinical trial, called rEECur, aims to find the most effective treatment for people in this situation. The study compares different cancer medicines against each other. Currently, it evaluates chemotherapy, such as ifosfamide, alongside a targeted drug called lenvatinib. By testing these treatments in an organised way, doctors want to find out which option gives patients the best chance of controlling the cancer, helps them live longer, and causes the fewest unpleasant side effects. People aged two and older who have Ewing sarcoma that has returned or resisted previous treatments may be able to take part.
At a glance
What is this study about?
Ewing sarcoma is a rare cancer that mostly affects children, teenagers, and young adults, though it can occur at any age. It usually starts in the bones or nearby soft tissues. When someone is first diagnosed, doctors use standard treatments like chemotherapy, surgery, and radiotherapy. While these treatments often work, the cancer can sometimes come back (recurrent) or stop responding to therapy (refractory). When this happens, there is no single agreed-upon 'best' next step, making it difficult for doctors to know which treatment will help the most.
The rEECur trial is a large, international study designed to answer that question. Instead of guessing which drug combination might work best, doctors are comparing different treatments directly against each other. Over time, the trial drops treatments that do not perform as well and adds promising new ones. At present, the trial is studying ifosfamide chemotherapy along with a targeted drug called lenvatinib, which works by cutting off the blood supply that tumours need to grow.
Studies like this are vital for improving cancer care. By learning which treatments provide the strongest attack against the cancer with the fewest unwanted side effects, researchers hope to establish a clear gold standard of care. This will help doctors worldwide offer the best possible treatment plan to patients and families facing recurrent Ewing sarcoma in the future.
Key takeaways
- The rEECur trial tests treatments for Ewing sarcoma that has returned or stopped responding to therapy.
- It is open to patients aged two and older who meet specific health and organ safety criteria.
- Treatments include chemotherapy drugs and targeted medicines designed to slow tumour growth.
- Participants are assigned to a treatment group by a fair, computer-controlled random process.
- Taking part is entirely voluntary, and you can withdraw at any time without affecting your normal care.
Who may be eligible?
This trial is open to adults and children aged two years and older who have been diagnosed with Ewing sarcoma or a very similar tumour in their bones or soft tissue. To be eligible, scans must show that the cancer has started growing again during or after previous treatment. Participants must also be well enough overall to cope with cancer treatment.
Because the drugs used can affect other parts of the body, safety is a top priority. Participants must have reasonably healthy kidneys, liver, and heart, as well as well-controlled blood pressure. These will all be checked with standard blood tests, urine checks, and heart scans before anyone starts the trial.
People cannot join if their body is not strong enough to tolerate the medicines or if their organ function falls below safe limits. Anyone who is pregnant cannot take part, and patients who are able to have children must agree to use reliable contraception during the study and for 12 months afterwards.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I (or my child) have a confirmed diagnosis of Ewing sarcoma or Ewing-like sarcoma.
- Scans show the tumour has returned or grown despite previous cancer treatment.
- The patient is at least two years of age.
- Kidneys, liver, and heart are functioning well enough for intensive treatment.
- Blood pressure is within a safe, controlled range.
- Willing and able to use reliable contraception if of childbearing age.
What does participation involve?
Taking part begins with a detailed health check, including blood tests, urine tests, an ultrasound scan of the heart (echocardiogram), and scans such as CT or MRI to measure the tumour. These tests confirm whether it is safe for you or your child to join. Once enrolled, a computer randomly selects which trial treatment you will receive. This process, called randomisation, ensures the comparison is fair and unbiased.
Treatment is given in regular cycles over several months. Chemotherapy is usually given as a drip into a vein during hospital visits or short inpatient stays. If lenvatinib is part of your treatment, it is taken daily by mouth as tablets or capsules at home. Throughout the trial, you will need frequent hospital visits for blood tests, physical exams, and regular scans to see how the cancer is responding. After treatment finishes, the study team will continue to monitor your health through routine follow-up appointments.
Potential risks and benefits
Locations (43)
- Christie HospitalApproximateManchester, England
- Addenbrooke's HospitalApproximateCambridge, England
- Alder Hey Children's HospitalCity onlyLiverpool, England
- Beatson West of Scotland Cancer CentreCity onlyGlasgow, Scotland
- Birmingham Children's HospitalApproximateBirmingham, England
- Bristol Royal Hospital for ChildrenUnverifiedBristol, England
- Churchill HospitalUnverifiedOxford, England
- Clatterbridge Cancer CentreUnverifiedBirkenhead, England
- Freeman HospitalUnverifiedNewcastle upon Tyne, England
- John Radcliffe HospitalUnverifiedOxford, England
- Leeds General InfirmaryUnverifiedLeeds, England
- Leicester Royal InfirmaryUnverifiedLeicester, England
Common questions
What is the rEECur trial?
It is a global clinical trial testing different cancer treatments to find the most effective option for Ewing sarcoma that has returned or not responded to prior therapy.
How will the doctors decide which treatment I get?
A computer uses a random process to choose your treatment group. This makes sure the study is fair and that the results can be trusted.
Can children join this study?
Yes, children aged two and older can join, provided they meet the general health and safety criteria.
What happens if I experience unpleasant side effects?
The care team watches you very closely. They can adjust your dose, offer medicines to relieve side effects, or pause treatment if necessary to protect your health.
What happens if I decide to stop taking part?
You can leave the trial at any point. Deciding to withdraw will never affect the quality of your NHS care or your relationship with your medical team.
How to find out more
Martin McCabe
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.